23ME610 by 23AndMe Holding for Metastatic Renal Cell Carcinoma: Likelihood of Approval

23ME610 is under clinical development by 23andMe Holding and currently in Phase II for Metastatic Renal Cell Carcinoma.

Today’s biotech news roundup, in under 800 words

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk lots

November 28, 2023

The U.S. hasn’t seen syphilis numbers this high since 1950. Other STD rates are down or flat

NEW YORK — The U.S. syphilis epidemic isn’t abating, with the rate of infectious cases rising 9% in 2022, according to a new federal government

January 30, 2024

Trump’s presidency return: boom or bust for biopharmaceutical deal activity?

On 5 November 2024, former US president Donald Trump was elected to a second term in the US presidential election. This marks the return of

November 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.